胃輕癱藥物市場 - 按藥物類別、疾病類型、給藥途徑、藥物類型、配銷通路- 全球預測

2024年至2032年，全球胃輕癱藥物市場的複合年成長率將超過5%。這項投資旨在滿足胃輕癱患者未滿足的醫療需求，胃輕癱是一種以胃排空延遲為特徵的疾病。

隨著藥物開發和治療策略的進步，製藥公司正在專注於創新治療方法以改善患者的治療效果。這些努力不僅促進了市場成長，而且還提高了治療胃輕癱的有效藥物的可用性，滿足了全球疾病盛行率上升和診斷進步推動的不斷成長的需求。

整個胃輕癱藥物產業根據藥物類別、疾病類型、給藥途徑、藥物類型、配銷通路和地區進行分類。

胃輕癱藥物市場的促動力劑部分將在 2024 年至 2032 年間保持顯著的複合年成長率，因為它們能有效增強胃動力，而胃動力是控制胃輕癱症狀的關鍵治療目標。促動力劑刺激胃腸收縮，從而促進更及時的胃排空並減輕噁心、嘔吐和腹脹等症狀。隨著製藥公司專注於開發和改進這些藥物，患者和醫療保健提供者越來越依賴它們來緩解症狀和提高生活品質。這種有針對性的方法強調了市場上對專門治療的需求不斷成長，推動了促進運動療法的進步。

到 2032 年，特發性胃輕癱產業將獲得重要的胃輕癱藥物市場佔有率，因為它是最常見的疾病形式，但確切原因尚不清楚。隨著認知和診斷的提高，越來越多的患者被診斷出患有特發性胃輕癱，導致對有效治療方案來控制其慢性症狀的需求增加。因此，製藥公司正專注於開發針對特發性胃輕癱潛在機制（例如胃動力障礙和胃排空受損）的療法。這種重視反映了對能夠解決該患者群體的特定挑戰的客製化治療的日益成長的需求。

2024年至2032年間，北美胃輕癱藥物市場將呈現強勁的複合年成長率。人口中胃輕癱盛行率較高的部分原因是生活方式因素和人口老化。此外，該地區先進的醫療基礎設施和強大的診斷能力可確保及早發現和開始治療，從而刺激需求。北美的製藥公司也處於研發前沿，並不斷創新以滿足患者不斷變化的需求。這些動態共同促進了北美市場的成長，使其成為市場擴張的關鍵地區。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 胃輕癱發生率上升
    • 患者對非侵入性治療的偏好日益成長
    • 意識和診斷率不斷提高
  • 產業陷阱與挑戰
    • 治療選擇有限
    • 監管挑戰
• 成長潛力分析
• 管道分析
• 監管環境
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 公司定位矩陣
• 戰略儀錶板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• 促動力劑
• 止吐藥
• 質子幫浦抑制劑
• 其他藥物類別

第 6 章：市場估計與預測：按疾病類型，2021 - 2032

• 主要趨勢
• 糖尿病胃輕癱
• 特發性胃輕癱
• 術後胃輕癱

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 口服
• 可注射
• 其他給藥途徑

第 8 章：市場估計與預測：按藥物類型，2021 - 2032

• 主要趨勢
• 非處方藥
• 處方藥

第 9 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 10 章：市場估計與預測：按地區，2021-2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：公司簡介

• Abbott Laboratories
• AbbVie Inc,
• AstraZeneca PLC
• Bayer AG
• Cipla Ltd.
• Evoke Pharma
• Pfizer Inc.
• Salix Pharmaceuticals
• Takeda Pharmaceutical Inc.
• Teva Pharmaceutical Inc.

Global Gastroparesis Drugs Market will register over 5% CAGR from 2024 to 2032. The market is expanding due to significant investments by pharmaceutical companies in research and development. This investment aims to meet the unmet medical needs of patients suffering from gastroparesis, a condition characterized by delayed stomach emptying.

With advancements in drug development and therapeutic strategies, pharmaceutical firms are focusing on innovative treatments to improve patient outcomes. These efforts not only usher market growth but also enhance the availability of effective medications for managing gastroparesis, catering to the increasing demand driven by rising disease prevalence and diagnostic advancements globally.

The overall Gastroparesis Drugs industry is classified based on drug class, disease type, route of administration, drug type, distribution channel, and region.

The pro kinetic agents segment in the gastroparesis drugs market will maintain a notable CAGR between 2024 and 2032, owing to their effectiveness in enhancing stomach motility, a critical therapeutic target for managing gastroparesis symptoms. pro kinetic agents stimulate gastrointestinal contractions, thus promoting more timely stomach emptying and alleviating symptoms such as nausea, vomiting, and bloating. As pharmaceutical companies focus on developing and improving these agents, patients and healthcare providers increasingly rely on them for symptom relief and improved quality of life. This targeted approach underscores the growing demand for specialized treatments within the market, driving advancements in pro-kinetic therapies.

By 2032, the idiopathic gastroparesis sector will secure a significant gastroparesis drugs market share because of its status as the most common form of the condition, where the exact cause is unknown. As awareness and diagnosis improve, more patients are identified with idiopathic gastroparesis, leading to an increased demand for effective treatment options to manage its chronic symptoms. Pharmaceutical companies are therefore focusing on developing therapies that target the underlying mechanisms of idiopathic gastroparesis, such as gastric dysmotility and impaired stomach emptying. This emphasis reflects a growing need for tailored treatments that address the specific challenges of this patient population.

Between 2024 and 2032, the North America gastroparesis drugs market will exhibit a strong CAGR. A higher prevalence of gastroparesis among the population is driven partly by lifestyle factors and an aging demographic. Additionally, advanced healthcare infrastructure and robust diagnostic capabilities in the region ensure early detection and treatment initiation, boosting demand. Pharmaceutical companies in North America are also at the forefront of research and development, continually innovating to meet the evolving needs of patients. These dynamics collectively contribute to the market growth in North America, making it a pivotal region for market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of gastroparesis
    • 3.2.1.2 Growing patient preference for non-invasive treatment
    • 3.2.1.3 Rising awareness and diagnosis rate
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Availability of limited treatment options
    • 3.2.2.2 Regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Company positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Prokinetic agents
• 5.3 Antiemetic drugs
• 5.4 Proton pump inhibitors
• 5.5 Other drug classes

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetes gastroparesis
• 6.3 Idiopathic gastroparesis
• 6.4 Post-surgical gastroparesis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 OTC drugs
• 8.3 Prescription drugs

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021- 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 The Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 AbbVie Inc,
• 11.3 AstraZeneca PLC
• 11.4 Bayer AG
• 11.5 Cipla Ltd.
• 11.6 Evoke Pharma
• 11.7 Pfizer Inc.
• 11.8 Salix Pharmaceuticals
• 11.9 Takeda Pharmaceutical Inc.
• 11.10 Teva Pharmaceutical Inc.